Human visceral leishmaniasis (VL) continues to be a life-threatening neglected tropical
disease, with close to 200 million people at risk of infection globally. Epidemics and …

Human visceral leishmaniasis (VL), a potentially fatal disease, is most prevalent in the
Indian subcontinent, East Africa and South America. Definite diagnosis and effective …

Visceral leishmaniasis continues to be an important public health problem worldwide. This
vector-borne infection affects approximately 500,000 people annually with more than 50,000 …

Visceral leishmaniasis (VL) is a systemic protozoan disease that is transmitted by
phlebotomine sandflies. Poor and neglected populations in East Africa and the Indian sub …

Visceral leishmaniasis (VL) or Kala‐azar, is the most lethal form of leishmaniasis, is still
prevalent in many countries where it is endemic. It is a threat to human life caused by …

Visceral leishmaniasis is common in less developed countries, with an estimated 500 000
new cases each year. Because of the diversity of epidemiological situations, no single …

This review summarizes the current developments in therapy for visceral leishmaniasis. With
the recent introduction of new drugs, the main limits in reducing deaths from visceral …

Limited therapeutic options in visceral leishmaniasis (VL) make the treatment of this
neglected disease very challenging. In addition to this, long treatment duration and toxic …

In 1990, there was essentially one treatment regimen in use for visceral leishmaniasis (kala-
azar) around the world: 20 to 28 days of daily injections of pentavalent antimony (Sb) …

Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging
with few treatment options. Long duration of treatment and drug toxicity further limit the target …